Stocks Health care VTVT
NASDAQ · Health carevTv Therapeutics Inc. (VTVT)
vTv Therapeutics Inc. brought in $36.8M of revenue over the twelve months to September 30, 2026, up 216,600.0% from a year earlier. It posted a net loss of $7.7M. At September 30, 2026 it held $77.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about vTv Therapeutics Inc.
- Net worth
- vTv Therapeutics Inc. has a market value (market cap) of $83.7M at the latest share price, and shareholders' equity of $69.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $0 (-100.0% year on year), with a net loss of $27M. Over the 12 months to September 30, 2026: revenue $36.8M, net loss $7.7M.
- Cash flow
- In fiscal 2025 operations used $25.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- vTv Therapeutics Inc.'s next report is expected around March 9, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What vTv Therapeutics Inc. does
vTv Therapeutics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker VTVT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$27M | n/a | n/a |
| 2024 | $1M | -$18.5M | n/a | -$25.3M |
| 2023 | $0 | -$20.3M | n/a | -$19.1M |
| 2022 | $2M | -$19.2M | n/a | -$16M |
| 2021 | $4M | -$13M | n/a | -$19.3M |
| 2020 | $6.4M | -$8.5M | n/a | -$18M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What vTv Therapeutics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026
- November 5, 2026
- October 8, 2026Passive stake changed SCHEDULE 13G/A
- October 6, 2026
- August 6, 2026
- August 6, 2026
- July 29, 2026Passive stake changed SCHEDULE 13G/A
- June 29, 2026
- June 10, 2026Additional proxy material DEFA14A
- May 13, 2026Other event 8-K
Insider trades
What the people running vTv Therapeutics Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns VTVT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| The ROP Revocable Trust dated 1/9/201813D, may seek influence with 7 related filers | 50.3% | March 22, 2024 |
| Samsara BioCapital, L.P.13D, may seek influence with 2 related filers | 10.4% | March 5, 2024 |
| Srinivas Akkaraju13D, may seek influence with 4 related filers | 9.9% | December 9, 2025 |
| Trails Edge Capital Partners, LP13G, passive with 2 related filers | 9.9% | September 8, 2025 |
| Raymond Debbane13G, passive with 7 related filers | 9.4% | November 12, 2025 |
| Millennium Management LLC13G, passive with 3 related filers | 8.7% | October 8, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 45 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Samsara Biocapital, LLC | 298,496 | 0 |
| Millennium Management LLC | 269,874 | +63,586 |
| Fmr LLC | 260,391 | 0 |
| Siren, L.L.C. | 163,000 | 0 |
| Baker Bros. Advisors LP | 148,314 | 0 |
| Vanguard Capital Management LLC | 94,463 | -14,459 |
| Trails Edge Capital Partners, LP | 85,192 | -54,386 |
| Aisling Capital Management LP | 50,000 | new |
| Marshall Wace, Llp | 39,560 | +26,171 |
| Geode Capital Management, LLC | 32,470 | -416 |
| Renaissance Technologies LLC | 17,454 | new |
| Vanguard Fiduciary Trust Co | 16,239 | +113 |
| BlackRock, Inc. | 14,731 | +2,129 |
| Jane Street Group, LLC | 13,703 | new |
| State Street Corp | 12,266 | +1,600 |
| Two Sigma Investments, LP | 11,486 | new |
| Verdad Advisers, LP | 8,996 | new |
| Integrated Quantitative Investments LLC | 8,210 | new |
| Susquehanna International Group, Llp | 8,023 | new |
| Quadrature Capital Ltd | 6,305 | new |
Insiders
Questions about VTVT
What does vTv Therapeutics Inc. do?
vTv Therapeutics Inc. is a company in the Health care sector, listed on NASDAQ as VTVT. Its shares trade on NASDAQ under the ticker VTVT.
What is vTv Therapeutics Inc.'s net worth?
vTv Therapeutics Inc. has a market value (market cap) of $83.7M at the latest share price, and shareholders' equity of $69.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is vTv Therapeutics Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $7.7M on revenue of $36.8M.
How much revenue does vTv Therapeutics Inc. make?
Over the twelve months to September 30, 2026 vTv Therapeutics Inc. reported revenue of $36.8M. That is 216,600.0% more than a year earlier.
When did vTv Therapeutics Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is vTv Therapeutics Inc.'s next earnings report?
vTv Therapeutics Inc.'s next report is expected around March 9, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare VTVT with
Follow VTVT
Get an email when vTv Therapeutics Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values vTv Therapeutics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.